key: cord-1019689-mid77l8k
authors: Wang, Zijun; Muecksch, Frauke; Muenn, Friederike; Cho, Alice; Zong, Shuai; Raspe, Raphael; Ramos, Victor; Johnson, Brianna; Tanfous, Tarek Ben; DaSilva, Justin; Bednarski, Eva; Guzman-Cardozo, Camila; Turroja, Martina; Millard, Katrina G.; Tober-Lau, Pinkus; Hillus, David; Yao, Kai-Hui; Shimeliovich, Irina; Dizon, Juan; Kaczynska, Anna; Jankovic, Mila; Gazumyan, Anna; Oliveira, Thiago Y.; Caskey, Marina; Bieniasz, Paul D.; Hatziioannou, Theodora; Kurth, Florian; Sander, Leif Erik; Nussenzweig, Michel C.; Gaebler, Christian
title: Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens
date: 2022-05-13
journal: bioRxiv
DOI: 10.1101/2022.05.13.491823
sha: 5db44fb6ada462e28eeec0e28d24d8c562f809f6
doc_id: 1019689
cord_uid: mid77l8k

The SARS-CoV-2 pandemic prompted a global vaccination effort and the development of numerous COVID-19 vaccines at an unprecedented scale and pace. As a result, current COVID- 19 vaccination regimens comprise diverse vaccine modalities, immunogen combinations and dosing intervals. Here, we compare vaccine-specific antibody and memory B cell responses following two-dose mRNA, single-dose Ad26.COV2.S and two-dose ChAdOx1 or combination ChAdOx1/mRNA vaccination. Plasma neutralizing activity as well as the magnitude, clonal composition and antibody maturation of the RBD-specific memory B cell compartment showed substantial differences between the vaccination regimens. While individual monoclonal antibodies derived from memory B cells exhibited similar binding affinities and neutralizing potency against Wuhan-Hu-1 SARS-CoV-2, there were significant differences in epitope specificity and neutralizing breadth against viral variants of concern. Although the ChAdOx1 vaccine was inferior to mRNA and Ad26.COV2.S in several respects, biochemical and structural analyses revealed enrichment in a subgroup of memory B cell neutralizing antibodies with distinct RBD-binding properties resulting in remarkable potency and breadth.

Coronavirus disease-2019 (COVID-19) vaccine programs are a historic public health success 43 that saved countless lives and prevented millions of Severe Acute Respiratory Syndrome 44

Coronavirus (SARS-CoV-2) infections (Vilches et al., 2022) . Vaccination is a multifaceted 45 global effort involving a diverse collection of vaccine platforms including mRNA, adenoviral 46 vector-based, inactivated virus and recombinant protein immunogens (Mathieu et al., 2021) . 47

Detailed evaluation of the different vaccine-specific immune responses will inform improved 48 vaccination strategies for the prevention of COVID-19 and other respiratory viral infections of 49 pandemic potential (Zhang et al., 2022) . 50 51 With close to 2.5 billion administered doses, the ChAdOx1 nCoV-19 (AZD1222) vaccine 52 accounted for over one third of all global COVID-19 vaccine doses administered in 2021 53 (Mallapaty et al., 2021; Mathieu et al., 2021) . The ChAdOx1 vaccine encodes full-length wild-54 type (Wuhan-Hu-1) SARS-CoV-2 spike protein without the prefusion-stabilizing mutations 55 found in the three US-approved vaccines (BNT162b2, mRNA-1273, and Ad26.COV2.S) 56 (Watanabe et al., 2021) . Outside of the US, ChAdOx1 received regulatory approval as a two-57 dose vaccine administered at an interval of 4-12 weeks. Unfortunately, ChAdOx1 vaccination 58 was associated with immune thrombocytopenia, a rare but serious complication that has been 59 described after administration of adenoviral vector vaccines. As a result, many individuals 60 receiving a ChAdOx1 prime were subsequently boosted with an mRNA vaccine (Klok et al., 61 2022) . 62

The combination (ChAdOx1/mRNA vaccine) prime-boost regimen showed enhanced 64 immunogenicity (Barros-Martins et al., 2021; Hillus et al., 2021; Normark et al., 2021; Schmidt 65 et al., 2021b) , however both ChadOx1-based vaccine regimens proved to be effective with 66 substantial protection against COVID-19 hospitalization and death (Andrews et al., 2022; 67 Nordstrom et al., 2021) . 68 69 In-depth analyses of antibody and memory B cell responses after natural infection, mRNA 70 (BNT162b2, mRNA-1273) and Janssen Ad26.COV2.S vaccination have been performed (Cho et 71 al., 2021; Gaebler et al., 2021; Muecksch et al., 2022; Robbiani et al., 2020; Wang et al., 2021c; 72 Wang et al., 2021d) . However, far less is known about the responses elicited by the ChadOx1 73 vaccine even though it was used in more countries that any other COVID-19 vaccine (Mathieu et 74 al., 2021) . Here, we compare vaccine-specific antibody and memory B cell responses to 2-dose 75 mRNA (BNT162b2 or mRNA-1273), 1-dose Janssen Ad26.COV2.S, 2-dose ChAdOx1 (AZ/AZ) 76 or ChAdOx1/BNT162b2 combination (AZ/BNT) vaccines. 77 78

Four cohorts of study participants with different vaccination regimens were recruited and 80 sampled prospectively. All cohorts included sampling time points at approximately 1 and 6 81 months after the 1 st vaccine dose. An additional sampling time point at 1 month after 2 nd 82 vaccination was available for the mRNA (1.3m after 2 nd dose=2.3m after 1 st dose), AZ/BNT and 83 AZ/AZ (1m after 2 nd dose=4m after 1 st dose) 2-dose vaccination regimens. The vaccination and 84 blood collection schedule for all cohorts in this study is depicted in Fig. 1a . 85

For the AZ/BNT and AZ/AZ cohort a total of 49 health-care workers with no prior history of 86 SARS-CoV-2-infection who received a ChAdOx1 vaccine prime followed by ChAdOx1 or 87 BNT162b2 boost 10-12-weeks later were enrolled in a prospective observational cohort study in 88 Berlin (Germany) (Hillus et al., 2021) . 23 and 26 study participants received ChAdOx1 or 89 mRNA as a second dose, respectively. Volunteers ranged in age from 20-65 years and were 65% 90 female. For detailed demographic information, see Methods and Table S1 and (Cho et al., 2022; 91 Muecksch et al., 2022) . 92 93 Plasma binding and Neutralization 94 doses of an mRNA vaccine but exceeded neutralizing titers of individuals that received a single 140 dose of the Janssen Ad26.COV2.S vaccine (Fig. 1h, i) . 141 142 Plasma neutralizing activity for 24 randomly selected samples (n=12, AZ/BNT; n=12, AZ/AZ) 143 was also assessed against SARS-CoV-2 Delta and Omicron BA.1 variants using viruses 144 pseudotyped with appropriate variant spikes (Cho et al., 2021; Schmidt et al., 2021a; Schmidt et 145 al., 2020; Wang et al., 2021d) . Four months after the initial AZ/BNT prime vaccination, 146 neutralizing titers against Delta and Omicron BA.1 were 5.5-, and 11.6-fold lower than against 147

Wuhan-Hu-1, with a further decrease to 5.6-and 13.6-fold lower activity at the 6-month time 148 point respectively . Similarly, AZ/AZ vaccination resulted in 5.8-and 21-149 fold lower neutralizing activity against Delta and Omicron BA.1 than against Wuhan-Hu-1 150 respectively at the 4-month time point. While Delta neutralization further decreased 6.4-fold 151 compared to Wuhan-Hu-1 at the 6-month time point, the neutralizing activity against Omicron 152 BA.1, which was initially very low, decreased to a lesser extent among AZ/AZ vaccinees (Fig. 153 1j-k, Fig. S1i-k) . 154

Remarkably, 1 month after the 2 nd vaccine dose Omicron BA.1 neutralizing titers in combination 156 AZ/BNT vaccinees exceeded neutralizing activity after AZ/AZ or 2-dose mRNA vaccination at 157 similar time points by 6.4-and 10.3-fold, respectively (p=0.003 and p<0.0001 Fig. 1l ). Omicron 158 BA.1 neutralizing titers remained higher in AZ/BNT vaccinees, but were not statistically 159 different from mRNA, or AZ/AZ vaccinees 6 months after the prime, while titers in Janssen 160

Ad26.COV2.S vaccinees were significantly lower (Fig. 1m) . 161 162

To compare the development of B cell memory after COVID-19 vaccination, we initially 164 enumerated memory B cells expressing surface receptors binding to the Receptor-Binding 165 Domain (RBD) and N-Terminal Domain (NTD) of the SARS-CoV-2 spike protein using 166 fluorescently labeled proteins (Fig. 2a, Fig. S2a-d) . The number of RBD-binding memory B cells 167 found in circulation 1 month after AZ prime was significantly lower than after mRNA 168 (p<0.0001, (Bednarski et al., 2022; Cho et al., 2021) ) and Janssen Ad26.COV2.S vaccination 169 (p=0.0029 (Cho et al., 2022) Table S2 ). Clonally expanded RBD-specific B cells 181 across the different vaccine regimens 6 months after prime represented 23%, 13%, 22% and 16% 182 of all memory cells from mRNA, Janssen Ad26.COV2.S, AZ/BNT and AZ/AZ vaccinees, 183 respectively (Fig. 2e ). Similar to mRNA and Janssen Ad26.COV2.S vaccinees, VH3-30, VH1-46 184 and VH3-53 genes were overrepresented among AZ/BNT and AZ/AZ vaccinees (Fig. S4 , (Cho 185 et al., 2021; Cho et al., 2022) ). There was no difference in the number of somatic mutations 186 between AZ/BNT or AZ/AZ vaccinees, although both groups showed significantly lower 187 accumulation of somatic mutations than mRNA or Janssen Ad26.COV2.S vaccinees assayed at 188 similar timepoints (p<0.0001, Fig. 2f Hu-1 RBD, indicating the high efficiency of RBD-specific memory B cell isolation (Table S3) . 201

The geometric mean ELISA half-maximal concentration (EC50) of the RBD-binding monoclonal 202 antibodies elicited by AZ/AZ or AZ/BNT vaccination was comparable (Fig. 3a) . EC50s represent 203 an indirect measure of affinity. To directly examine anti-RBD antibody affinity, we performed 204 biolayer interferometry (BLI) experiments on a subset of antibodies (n=66 from AZ/BNT and 205 n=62 from AZ/AZ). Affinity was comparable among antibodies elicited by mRNA, Janssen 206

Ad26.COV2.S, and AZ/BNT or AZ/AZ vaccination (Fig. 3b , (Cho et al., 2021) ). All 277 binding IgG monoclonal antibodies were tested for neutralization against viruses pseudotyped 208 with Wuhan-Hu-1 SARS-CoV-2 spike protein (183 and 94 antibodies isolated from AZ/BNT 209 and AZ/AZ vaccinees, respectively). Memory B cell antibodies elicited by mRNA, Janssen 210

Ad26.COV2.S, AZ/BNT and AZ/AZ vaccination 6 months after the prime showed comparable 211 activity (Fig 3c) . Similarly, the proportion of neutralizing to non-neutralizing antibodies for all 212 four regimens was not significantly different (Fig. 3d) . We conclude that memory B cells present 213 in circulation 6 months after initial mRNA, Janssen Ad26.COV2.S, AZ/AZ and AZ/BNT 214 vaccine doses express antibodies with similar binding affinities and neutralizing potency against 215

Wuhan-Hu-1 SARS-CoV-2. 216 217

SARS-CoV-2 infection and vaccination elicit anti-RBD antibodies that target four structurally 219 defined classes of epitopes on the RBD (Barnes et al., 2020; Muecksch et al., 2022; Muecksch et 220 al., 2021; Wang et al., 2021c; Yuan et al., 2020) . Class 1 and 2 antibodies block ACE2 binding 221 directly, and Class 3 and 4 antibodies target more conserved regions on the RBD (Gaebler et al., 222 2021; Muecksch et al., 2022; Muecksch et al., 2021; Wang et al., 2021c) . Class 1 and 2 223 antibodies develop early after infection or mRNA-immunization (Muecksch et al., 2022) , while 224 Janssen Ad26.COV2.S vaccination leads to a more diverse, early memory B cell response that is 225 dominated by Class 3 and 4 antibodies (Cho et al., 2022) . Nevertheless, continued memory B 226 cell evolution results in comparable epitope specificities 5-6 months after the initial mRNA or 227 Janssen Ad26.COV2.S immunization (Cho et al., 2022) . 228

To define the epitopes recognized by anti-RBD memory antibodies elicited by AZ/BNT or 230 AZ/AZ vaccination, we performed BLI competition experiments. A preformed antibody-RBD-231 complex was exposed to a second antibody targeting one of four classes of structurally defined 232 epitopes (Barnes et al., 2020; Robbiani et al., 2020 ) (C105 as Class 1; C144 as Class 2; C135 as 233 Class 3; and CR3022 as Class 4). We examined 128 RBD-binding antibodies randomly obtained 234 from the AZ/BNT (n=66) and AZ/AZ (n=62) vaccinees. This included AZ/BNT (n=44) and 235 AZ/AZ (n=39) antibodies with IC50s less than 1000 ng/mL. 236

The epitope distribution of the memory antibody repertoires was significantly different between 238 all four vaccine regimens (Fig. S5a) . Moreover, the overall epitope specificities of the antibody 239 repertoires were significantly different between mRNA vaccinees and AZ/BNT or AZ/AZ 240 vaccinees (Fig. 4a ). This was particularly evident among neutralizing (IC50<1000ng/ml) 241 antibodies for which the frequency of antibodies that target unknown epitopes (non-classified) 242 was highly enriched in the antibody repertoire isolated from AZ/BNT or AZ/AZ vaccinees (Fig.  243 4a). At the same time, there were no significant differences in epitope specificities for non-244 neutralizing (IC50>1000 ng/ml) antibodies. 245

To examine the contribution of the different antibody classes to the neutralizing potency and 247 breadth elicited by each of the four vaccine regimens, we regrouped the antibodies as follows: 1) 248

Antibodies targeting Class 1 and/or 2 epitopes; 2) antibodies additionally or exclusively targeting 249 Class 3 epitopes; 3) antibodies additionally or exclusively targeting Class 4 epitopes; or 4) non-250 classifiable antibodies. While neutralizing potency of the first 3 groups was comparable among 251 all four vaccines regimens, AZ/BNT and AZ/AZ vaccination elicited non-classifiable antibodies 252 that were significantly more potent than their mRNA or Janssen counterparts (Fig. 4b) . 

To understand the interaction between these none-classified antibodies and RBD, we imaged WT 276

Wuhan-Hu-1 SARS-CoV-2 S 6P bound to Fab fragments of a potent and broad AZ/AZ antibody 277 (AZ090) by single-particle cryo-electron microscopy (cryo-EM) ( Fig. 5a and Fig. S6 ). The 278 resolution of the reconstituted cryo-EM electron density map was 3 Å for the whole complex and 279 the spike-AZ090. Structural analyses of the density maps showed that the binding orientation of 280 AZ090 is similar to previously described potent antibodies that were isolated following natural 281 infection (Dejnirattisai et al., 2021; Reincke et al., 2022; Tortorici et al., 2020; Wang et al., 282 2021a) (Fig. S7 ). AZ090 and this type of antibodies share the same immunoglobulin heavy and Neutralizing antibodies are correlates of vaccine efficacy in protection against SARS-CoV-2 291 infection and severe COVID-19 (Bergwerk et al., 2021; Feng et al., 2021; Khoury et al., 2021; Li 292 et al., 2022) . All three US-authorized vaccines have shown substantial protection against SARS-293

CoV-2 infection, hospitalization, and death (Botton et al., 2022; Self et al., 2021) . However, 294 vaccine efficacy wanes over time with prominent loss of protection against infection after the 295 Janssen Ad26.COV2.S vaccine compared to mRNA (Lin et al., 2022) . Similarly, vaccination 296 regimens with the globally predominant ChAdOx1vaccine have been less effective in the 297 protection against infection and symptomatic COVID-19 compared to mRNA vaccination 298 (Andrews et al., 2022; Braeye et al., 2022) . However, the combination of a ChAdOx1 prime and 299 a 2 nd mRNA dose shows similar levels of protection as 2-dose mRNA vaccination (Nordstrom et 300 al., 2021) . 301 302 Our comparative analysis of plasma and memory B cell antibodies provides a mechanistic 303 explanation for the observed real-world protective efficacy of the several different vaccine 304 regimens. Binding and neutralizing antibody levels elicited by 2-dose mRNA or AZ/BNT 305 vaccination exceeds those elicited by AZ/AZ or single-dose Janssen Ad26.COV2.S vaccination. 306

Omicron BA.1 neutralization was highest after AZ/BNT vaccination suggesting that combination 307 vaccine protocols with extended dosing intervals may induce improved plasma neutralizing 308 responses. In line with our observation, vaccine efficacy has been shown to increase with the 309 interval between the 1 st and 2 nd vaccine dose (Voysey et al., 2021) . Prolonged affinity maturation 310 yielding higher affinity B cells for plasma cell maturation upon the administration of the 2nd 311 vaccine dose may be of importance in this process (Hall et al., 2022) . 312

The relative potency and breadth, i.e. neutralizing activity against Delta and Omicron, of 314 memory B cell antibodies produced by the 4 different vaccine regimens was overall similar. 315 However, they differed in the absolute number of memory cells and the distribution of the RBD 316 epitopes targeted by mRNA, Janssen Ad26.COV2.S and ChAdOx1 vaccination regimens. 317

Differences in dosing intervals between prime and boost immunization, distinct antigenic 318 features of the full-length wild-type SARS-CoV-2 spike protein lacking prefusion-stabilizing 319 mutations in the ChAdOx1 vaccine (Tortorici and Veesler, 2019) , and the precise biochemistry 320 of the antigen and its presentation may all contribute to these observations. 321 322 Notably, the number of RBD-binding memory cells that develop after 2-dose mRNA vaccination 323 is greater than vaccination regimens that are based on adenoviral vectors. The latter is likely to 324 be particularly important for recall responses and protection from severe diseases upon repeated 325 viral challenge (Amanna et al., 2007; Mesin et al., 2020) . for plasma IgG antibody binding to SARS-CoV-2 Wuhan-Hu-1 RBD 1 month (m) after mRNA 335 prime (Cho et al., 2021) , or Janssen Ad26.COV.2S prime (Cho et al., 2022) or AZ prime, as well 336 as 4 months or 6 months after the initial AZ prime (AZ/BNT; n=26) or (AZ/AZ; n=23). Lines 337 connect longitudinal samples. c-e, AUC for plasma IgG binding to Wuhan-Hu-1 RBD in vaccinees 338 1 m after AZ prime compared to mRNA prime (Cho et al., 2021) or Janssen Ad26.COV2.S (Cho 339 et al., 2022) prime at similar timepoint (c) , mRNA vaccinees 2.3 m after initial dose (Cho et al., 340 2021) compared to AZ/BNT and AZ/AZ vaccinees 4 m after initial dose (d), or mRNA vaccinees 341 6 m after initial dose (Cho et al., 2021) and Janssen Ad26.COV2.S vaccinees 6 m after one dose 342 (Cho et al., 2022) compared to AZ/BNT and AZ/AZ vaccinees 6 m after initial dose (e). f-i, Anti-343 SARS-CoV-2 NT50s of plasma measured by a SARS-CoV-2 pseudotype virus neutralization assay 344 using wild-type (Wuhan-Hu-1 (Wu et al., 2020) ) SARS-CoV-2 pseudovirus (Robbiani et al., 2020; 345 Schmidt et al., 2020) in plasma samples shown in panels a-e. j-m, Plasma neutralizing activity 346 against indicated SARS-CoV-2 Delta (j) and Omicron (k) variants for n=24 (AZ/BNT: n=12 and 347 AZ/AZ:n=12) randomly selected samples assayed in HT1080Ace2 cl.14 cells. l-m, mRNA 348 vaccinees 2.3 m after initial dose (Cho et al., 2021) compared to AZ/BNT and AZ/AZ vaccinees 349 4 m after initial dose (l), or mRNA vaccinees 6 m (Cho et al., 2021) and Janssen Ad26.COV2.S 350 vaccinees 6 m after initial dose (Cho et al., 2022) Hu-1 RBD measured by BLI for antibodies cloned from mRNA vaccinees 6 months(m) after initial 395 dose (n=43) (Cho et al., 2021) , from Janssen Ad26.COV2.S vaccinees 6 m (n=33) after prime 396 (Cho et al., 2022) , compared to antibodies cloned from AZ/BNT (n=189) and AZ/AZ (n=94) 397 vaccinees 6 m after initial dose. c, Graphs show anti-SARS-CoV-2 neutralizing activity of 398 monoclonal antibodies measured by a SARS-CoV-2 pseudotype virus neutralization assay using 399 wild-type (Wuhan-Hu-1 (Wu et al., 2020) ) (SARS-CoV-2 pseudovirus (Robbiani et al., 2020; 400 Schmidt et al., 2020) ) for antibodies cloned from mRNA vaccinees and 6 m after initial dose 401 (n=262) (Cho et al., 2021) , or from Janssen Ad26.COV2.S vaccinees (n=95) 6 m after prime (Cho 402 et al., 2022) , compared to antibodies cloned from AZ/BNT (n=189) and AZ/AZ (n=94) vaccinees 403 6 m after initial dose. d. Pie charts indicated the frequency of neutralizing (IC50<1000 ng/mL, 404 white) vs. non-neutralizing (IC50>1000 ng/mL, black) antibodies cloned from mRNA 405 vaccinees (Cho et al., 2021) , Janssen Ad26.COV2.S vaccinees (Cho et al., 2022) Results of epitope mapping performed by competition BLI, comparing mAbs cloned from Janssen 415 vaccinees 6 m (n=33) after prime (Cho et al., 2022) and mAbs cloned from mRNA vaccinees 6 m 416 after initial dose (n=68) (Cho et al., 2021) , to mAbs cloned from AZ/AZ (n=62) or AZ/BNT(n=66) 417 vaccinees 6 m after initial dose. a, Pie charts show the distribution of the antibody classes among 418 all RBD-binding antibodies, Wuhan-Hu-1 neutralizing antibodies only or non-neutralizing 419 antibodies only. Statistical significance was determined by using a two-tailed Chi-square test. b, 420

Graphs showing IC50 neutralization activity of antibodies indicated in a and Fig. S5a , with 4 421 categories by combining 1) C1/2 or C1 or C2 as C1/2; 2) C1/2/3 or C3 or C2/3 as C1/2/3; 3) C1/2/4 422 or C4 or C1/4 as C1/2/4; 4) Non-classified and C1/2/3/4 as non-classified. c, Heat-maps show 423

IC50s of antibodies obtained from AZ/BNT vaccinees (n=32), and AZ/BNT vaccinees (n=34) IgG 4 m and 6 m after initial dose for all male (M: n=9) or female (F: n=14) following the AZ/AZ 462 scheme (right panel). g-h, Interval between first and second vaccination (X axis) plotted against 463 AUC for anti-RBD IgG (Y axis) at 4 m and 6 m after initial dose following g, the AZ/BNT scheme, 464 or h, the AZ/AZ scheme. i-k, Plasma neutralizing activity against indicated SARS-CoV-2 variants 465 of interest/concern for n=12 randomly selected samples assayed in HT1080Ace2 cl.14 cells. 466

Viruses in i-k contained the R683G furin cleavage site mutation to increase particle infectivity. 467 (See also in Fig. 1j-m) Soto et al (Soto et al., 2019) . Graph shows relative abundance of human IGHV, IGKV and IGLV 508 genes, with 6 m AZ/AZ antibodies (blue) and AZ/BNT antibodies (green). a, Sequence Read 509 Archive accession SRP010970(orange); b, antibodies from mRNA vaccinees 6 months(m) after 510 initial dose (orange) (Cho et al., 2021) ; c, antibodies from Janssen Ad26.COV2.S vaccinees 6 m 511 after prime (orange) (Cho et al., 2022) . Statistical significance was determined by two-sided 512 binomial test. * = p≤0.05, ** = p≤0.01, *** = p≤0.001, **** = p≤0.0001. antibodies obtained from mRNA vaccinees at 6 m after initial dose (n=68) (Cho et al., 2021), 522 Janssen vaccinees at 6 m (n=33) after prime (Cho et al., 2022) , to mAbs cloned from AZ/AZ 523 (n=62) or AZ/BNT(n=66) vaccinees 6 m after initial dose. Pie charts were compared using a two-524 tailed Fisher's exact test. (ICH 1996) and the 556 Declaration of Helsinki. Health-care workers at Charité-Universitätsmedizin Berlin were offered 557 either two doses of BNT162b2 3 weeks apart or an initial dose of ChAdOx1 nCov-19 followed 558 by a heterologous boost with BNT162b2 10-12 weeks later. The vaccine regimen depended on 559 availability and current official recommendations. Health-care workers who received an initial 560 dose of ChAdOx1 nCov-19 were also free to choose a homologous booster with ChAdOx1 561 nCov-19 10-12 weeks later. (Hillus et al., 2021) For detailed participant characteristics see Table  562 S1 and previous publications (Cho et al., 2021; Cho et al., 2022; Muecksch et al., 2022) Enzyme-Linked Immunosorbent Assays (ELISAs) (Amanat et al., 2020; Grifoni et al., 2020) to 576 evaluate antibodies binding to SARS-CoV-2 RBD were performed by coating of high-binding 577 96-half-well plates (Corning 3690) with 50 μl per well of a 1μg/ml protein solution in Phosphate-578 buffered Saline (PBS) overnight at 4°C. Plates were washed 6 times with washing buffer (1× 579 PBS with 0.05% Tween-20 (Sigma-Aldrich)) and incubated with 170 μl per well blocking buffer 580 (1× PBS with 2% BSA and 0.05% Tween-20 (Sigma)) for 1 hour at room temperature. 581

Immediately after blocking, monoclonal antibodies or plasma samples were added in PBS and 582 incubated for 1 hour at room temperature. Plasma samples were assayed at a 1:66 starting 583 dilution and 10 additional threefold serial dilutions. Monoclonal antibodies were tested at 10 584 μg/ml starting concentration and 10 additional fourfold serial dilutions. Plates were washed 6 585 times with washing buffer and then incubated with anti-human IgG, IgM or IgA secondary 586 antibody conjugated to horseradish peroxidase (HRP) 587 109-035-129, and Sigma A0295) in blocking buffer at a 1:5,000 dilution (IgM and IgG) or 588 1:3,000 dilution (IgA). Plates were developed by addition of the HRP substrate, 3,3',5,5'-589 Tetramethylbenzidine (TMB) (ThermoFisher) for 10 minutes (plasma samples) or 4 minutes 590 (monoclonal antibodies). The developing reaction was stopped by adding 50 μl of 1 M H2SO4 591 and absorbance was measured at 450 nm with an ELISA microplate reader (FluoStar Omega, 592 BMG Labtech) with Omega and Omega MARS software for analysis. For plasma samples, a 593 positive control (plasma from participant COV72, diluted 66.6-fold and ten additional threefold 594 serial dilutions in PBS) was added to every assay plate for normalization. The average of its 595 signal was used for normalization of all the other values on the same plate with Excel software 596 before calculating the area under the curve using Prism V9.1 (GraphPad). Negative controls of 597 pre-pandemic plasma samples from healthy donors were used for validation (for more details, 598 please see (Robbiani et al., 2020) ). For monoclonal antibodies, the ELISA half-maximal 599 concentration (EC50) was determined using four-parameter nonlinear regression (GraphPad 600 Prism V9.1). EC50s above 1000 ng/mL were considered non-binders. 601 602

The mammalian expression vector encoding the Receptor Binding-Domain (RBD) of SARS-604

CoV-2 (GenBank MN985325.1; Spike (S) protein residues 319-539) was previously described 605 (Barnes et al., 2020) . Mammalian expression vector encoding the SARS-CoV-2 Wuhan-Hu-1 606 NTD (GenBank MN985325.1; S protein residues 14-307) was previously described (Wang et al., 607 2022a) . 608

A panel of plasmids expressing RBD-mutant SARS-CoV-2 spike proteins in the context of 611 pSARS-CoV-2-S Δ19 has been described (Cho et al., 2021; Muecksch et al., 2021; Wang et al., 612 2021d; Weisblum et al., 2020) . Variant pseudoviruses resembling SARS-CoV-2 variants Delta 613 (B.1.617.2) and Omicron BA.1 (B.1.1.529) have been described before (Cho et al., 2021; 614 Schmidt et al., 2021a; Wang et al., 2021c) Deletions/substitutions corresponding to variants of concern listed above, were incorporated into 624 a spike protein that also includes the R683G substitution, which disrupts the furin cleavage site 625 and increases particle infectivity. Neutralizing activity against mutant pseudoviruses were 626 compared to a wildtype (WT) SARS-CoV-2 spike sequence (NC_045512), carrying R683G 627 where appropriate. 628 629 SARS-CoV-2 pseudotyped particles were generated as previously described (Robbiani et al., 630 2020; Schmidt et al., 2020) . Briefly, 293T (CRL-11268) cells were obtained from ATCC, and 631 the cells were transfected with pNL4-3 ΔEnv-nanoluc and pSARS-CoV-2-SΔ19. Particles were 632 harvested 48 hours post-transfection, filtered and stored at -80°C. 633 634

Four-to five-fold serially diluted pre-pandemic negative control plasma from healthy donors, 636 plasma from individuals who received Ad26.COV2.S vaccines, or monoclonal antibodies were 637 incubated with SARS-CoV-2 pseudotyped virus for 1 hour at 37 °C. The mixture was 638 subsequently incubated with 293TAce2 cells (Robbiani et al., 2020) (for all WT neutralization 639 assays) or HT1080Ace2 cl14 (for all mutant panels and variant neutralization assays) cells 640 (Wang et al., 2021d) Purified and Avi-tagged SARS-CoV-2 Wuhan-Hu-1 RBD and NTD were biotinylated using the 652 Biotin-Protein Ligase-BIRA kit according to manufacturer's instructions (Avidity) as described 653

before (Robbiani et al., 2020) . Ovalbumin (Sigma, A5503-1G) was biotinylated using the EZ-654 Link Sulfo-NHS-LC-Biotinylation kit according to the manufacturer's instructions (Thermo 655 Scientific). Biotinylated ovalbumin was conjugated to streptavidin-BB515 (BD, 564453). RBD 656 was conjugated to streptavidin-PE (BD Biosciences, 554061) and streptavidin-AF647 657 (Biolegend, 405237) (Robbiani et al., 2020) . NTD was conjugated to streptavidin-BV421 658 (Biolegend, 405225) and streptavidin-BV711 (BD Biosciences, 563262). 659 660

Single-cell sorting by flow cytometry was described previously (Robbiani et al., 2020) . Briefly, 662 peripheral blood mononuclear cells were enriched for B cells by negative selection using a pan-663 B-cell isolation kit according to the manufacturer's instructions (Miltenyi Biotec, . Antibodies were identified and sequenced as described previously (Robbiani et al., 2020; Wang 681 et al., 2021b) . In brief, RNA from single cells was reverse-transcribed (SuperScript III Reverse 682

Transcriptase, Invitrogen, 18080-044) and the cDNA was stored at −20 °C or used for 683 subsequent amplification of the variable IGH, IGL and IGK genes by nested PCR and Sanger 684 sequencing. Sequence analysis was performed using MacVector. Amplicons from the first PCR 685 reaction were used as templates for sequence-and ligation-independent cloning into antibody 686 expression vectors. Recombinant monoclonal antibodies were produced and purified as 687 previously described (Robbiani et al., 2020) . 688 689

Biolayer interferometry assays were performed as previously described (Robbiani et al., 2020) . 691

Briefly, we used the Octet Red instrument (ForteBio) at 30°C with shaking at 1,000 r.p.m. 692

Epitope binding assays were performed with protein A biosensor (ForteBio 18-5010), following 693 the manufacturer's protocol "classical sandwich assay" as follows: (1) Stabilized SARS-CoV-2 6P ectodomain and Fabs were expressed and purified as previously 712 described (Wang et al., 2022b) . Briefly, constructs encoding the stabilized spike of SARS-CoV-2 713 ectodomain (Hsieh et al., 2020) were used to transiently transfect Expi293F cells (Gibco). 714

Supernatants were harvested after four days, and S 6P proteins were purified by nickel affinity 715 following with size-exclusion chromatography. Peak fractions from size-exclusion 716 chromatography were identified by native gel analysis for spike trimer fractions. 717 718

Purified Fabs were mixed with S 6P protein at a 1.1:1 M ratio of Fab-to-protomer for 30 min at 720 room temperature. Fab-S complexes were deposited on a freshly glow-discharged 400 mesh, 721 1.2/1.3 Quantifoil grid (Electron Microscopy Sciences). Immediately prior to deposition of 3 mL 722 of complex onto grid, fluorinated octyl-maltoside (Anatrace) was added to the sample to a final 723 concentration of 0.02% w/v. Samples were vitrified in 100% liquid ethane using a Mark IV 724 Vitrobot (Thermo Fisher) after blotting at 22 C° and 100% humidity for 3s with filter paper. 725 726 Cryo-EM data collection and processing 727

Single-particle cryo-EM data were collected on a Titan Krios transmission electron microscope 728 (Thermo Fisher) equipped with a Gatan K3 direct detector, operating at 300 kV and controlled 729 using SerialEM automated data collection software (Mastronarde, 2005) . A total dose of 56.56 730 e/Å 2 was accumulated on each movie with a pixel size of 0.515 and a defocus range of -0.8 and 731

2.0 µm. Movie frame alignment, CTF estimation, particle-picking and extraction were carried 732 out using cryoSPARC v3.3.1 (Punjani et al., 2017 ). Reference-free particle picking and extraction 733 were performed on dose-weighted micrographs. A subset of 4x-downsampled particles were 734 used to conduct several rounds of reference-free 2D classification, then the selected Fab-S 735 particles were extracted, 2x-downsampled, yielding a pixel size of 1.03 Å. The particles were 736 used to generate ab initio models, which were then used for heterogeneous refinement of the 737 entire dataset in cryoSPARC. Particles belonging to classes that resembled Fab-S structures were 738 homogeneous refined following with non-uniform refinement until imported into Relion 3.1.3 739 for CTF refinement. The particles were then imported into cryoSPARC for heterogenerous 740 refinement. Particles belonging to classes with better Fab density were selected and subjected to 741 another round of homogeneous refinement following with non-uniform refinement. To improve 742 the density of the RBD/AZ090interface, several rounds of local refinement were then performed 743 using different soft masks. Reported resolutions are based on the gold-standard Fourier shell 744 correlation of 0.143 criterion (Bell et al., 2016) . 745 746 Cryo-EM structure modeling and analysis 747 UCSF Chimera (Pettersen et al., 2004) and Coot (Emsley et al., 2010) were used to fit atomic 748 models into the locally refined cryoEM map. Models were refined and validated by 749

Phenix (Liebschner et al., 2019) . Figures were generated using UCSF ChimeraX (Goddard et al., 750 2018) . 751 752

Antibody sequences were trimmed based on quality and annotated using Igblastn v.1.14. with 754 IMGT domain delineation system. Annotation was performed systematically using Change-O 755 toolkit v.0.4.540 (Gupta et al., 2015) . Clonality of heavy and light chain was determined using 756 DefineClones.py implemented by Change-O v0.4.5 (Gupta et al., 2015) . The script calculates the 757

Hamming distance between each sequence in the data set and its nearest neighbor. Distances are 758 subsequently normalized and to account for differences in junction sequence length, and 759 clonality is determined based on a cut-off threshold of 0.15. Heavy and light chains derived from 760 the same cell were subsequently paired, and clonotypes were assigned based on their V and J 761 genes using in-house R and Perl scripts. All scripts and the data used to process antibody 762 sequences are publicly available on GitHub 763 (https://github.com/stratust/igpipeline/tree/igpipeline2_timepoint_v2). 764

The frequency distributions of human V genes in anti-SARS-CoV-2 antibodies from this study 765 was compared to 131,284,220 IgH and IgL sequences generated by (Soto et al., 2019) and 766 downloaded from cAb-Rep , a database of human shared BCR clonotypes 767 available at https://cab-rep.c2b2.columbia.edu/. Based on the 150 distinct V genes that make up 768 the 1099 analyzed sequences from Ig repertoire of the 6 participants present in this study, we 769 selected the IgH and IgL sequences from the database that are partially coded by the same V 770 genes and counted them according to the constant region. The frequencies shown in Fig. S4 are 771 relative to the source and isotype analyzed. We used the two-sided binomial test to check 772 whether the number of sequences belonging to a specific IGHV or IGLV gene in the repertoire is 773 different according to the frequency of the same IgV gene in the database. 

cAb-Rep

A 845 serological assay to detect SARS-CoV-2 seroconversion in humans

Duration of humoral immunity to common 848 viral and vaccine antigens

Duration of Protection against Mild and Severe Disease by Covid-853 19 Vaccines

SARS-CoV-2 neutralizing 857 antibody structures inform therapeutic strategies

Immune responses against SARS-CoV-2 variants after 863 heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

Antibody and memory B-cell immunity in a heterogeneously SARS-CoV-2 871 infected and vaccinated population

High resolution single particle 873 refinement in EMAN2

Covid-19 Breakthrough Infections in Vaccinated 877 Health Care Workers

Effectiveness of Ad26.COV2.S Vaccine vs BNT162b2 Vaccine

Vaccine effectiveness against onward 884 transmission of SARS-CoV2-infection by variant of concern and time since vaccination

Anti-SARS-CoV-2 receptor-binding domain antibody evolution 891 after mRNA vaccination

Antibody evolution to 896 SARS-CoV-2 after single-dose Ad26

The 905 antigenic anatomy of SARS-CoV-2 receptor binding domain

A Public Database of 908 Memory and Naive B-Cell Receptor Sequences

Features and development of Coot

Correlates of protection against symptomatic and asymptomatic SARS-915 CoV-2 infection

Evolution of antibody immunity to 923 SARS-CoV-2

UCSF ChimeraX: Meeting modern challenges in visualization and analysis

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with 931 COVID-19 Disease and Unexposed Individuals

Curated Antibody Repertoires for Exploring Antibody Diversity and Predicting Antibody 934 Prevalence

Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire 937 sequencing data

Delayed-interval BNT162b2 mRNA 940 COVID-19 vaccination enhances humoral immunity and induces robust T cell responses

Safety, 946 reactogenicity, and immunogenicity of homologous and heterologous prime-boost 947 immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study

Structure-based design 953 of prefusion-stabilized SARS-CoV-2 spikes

2022. 956 Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-957 1273 vaccination

Neutralizing antibody levels are highly 960 predictive of immune protection from symptomatic SARS-CoV-2 infection

Vaccine-induced immune thrombotic 963 thrombocytopenia

Neutralizing Antibodies for COVID-19 Prevention and Treatment

Macromolecular structure determination using X-rays, neutrons and electrons: recent 972 developments in Phenix

Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina

How 977 COVID vaccines shaped 2021 in eight powerful charts

A global database of COVID-19 vaccinations

2022. 988 Increased Memory B Cell Potency and Breadth After a SARS-CoV-2 mRNA Boost

Affinity maturation of SARS-CoV-2 neutralizing 995 antibodies confers potency, breadth, and resilience to viral escape mutations

Effectiveness of heterologous ChAdOx1 998 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in 999 Sweden: A nationwide cohort study

Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination

UCSF Chimera--a visualization system for exploratory research and 1006 analysis

Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination

2017. cryoSPARC: algorithms for 1014 rapid unsupervised cryo-EM structure determination

SARS-CoV-2 Beta variant infection elicits potent lineage-specific and 1021 cross-reactive antibodies

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Plasma Neutralization of the SARS-CoV-2 Omicron Variant

Measuring SARS-CoV-2 neutralizing antibody 1038 activity using pseudotyped and chimeric viruses

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-1042 19/mRNA vaccination

Comparative Effectiveness of Moderna

Hospitalizations Among Adults Without Immunocompromising Conditions -United 1055

Fast, scalable generation 1058 of high-quality protein multiple sequence alignments using Clustal Omega

High frequency of shared clonotypes in 1062 human B cell receptor repertoires

Ultrapotent 1070 human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

Chapter Four -Structural insights into coronavirus entry

Estimating COVID-19 Infections, Hospitalizations, and Deaths Following 1076 the US Vaccination Campaigns During the Pandemic

Single-dose administration and the influence of the timing of the 1193 booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) 1194 vaccine: a pooled analysis of four randomised trials

Ultrapotent antibodies against 1204 diverse and highly transmissible SARS-CoV-2 variants

Enhanced SARS-CoV-2 neutralization by dimeric IgA

Conserved Neutralizing Epitopes on the N-Terminal Domain of 1215 Variant SARS-CoV-2 Spike Proteins

Analysis of memory B cells identifies conserved neutralizing 1221 epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins

Naturally enhanced neutralizing breadth against SARS-CoV-2 one 1227 year after infection

mRNA vaccine-elicited 1234 antibodies to SARS-CoV-2 and circulating variants

Native-like SARS-CoV-2 Spike Glycoprotein 1239 Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine

Escape from 1244 neutralizing antibodies by SARS-CoV-2 spike protein variants

A new coronavirus associated with human respiratory disease in 1248 China

Structural 1251 basis of a shared antibody response to SARS-CoV-2

Humoral and cellular immune 1255 memory to four COVID-19 vaccines. bioRxiv 2022